Jim O’Neill Is “Free For Global AMR Role” After Leaving UK Government
Executive Summary
Having suddenly resigned from the UK Government Jim O’Neill says he’s now available to take on a global role, if asked, to promote concrete action on tackling antimicrobial resistance within promised timeframes.
You may also be interested in...
13 Pharmas Sign Roadmap For Antibiotic Reform – But What Do They Want?
More than 13 global pharma companies, including GlaxoSmithKline, Pfizer and Merck & Co., have agreed a "Roadmap" aimed at relieving the growing antimicrobial resistance crisis worldwide – as well as principles to explore alternative business models and incentives for antibiotic R&D and reimbursement.
UN Countries Make Bold Pledges On AMR, Including Funding For R&D Into New Drugs and Diagnostics
During the high-level UN meeting on Sept. 21, all 193 member countries will sign a declaration in which they pledge to take concrete action on tackling antimicrobial resistance, including providing resources for research into new drugs, vaccines and diagnostics, and ensuring good stewardship of antibiotic use in both humans and animals.
Final O'Neill Review Suggests Supra-National AMR Body & Pharma Levy
Antimicrobial Resistance (AMR) is a huge economic and security threat necessitating immediate coordinated action and pooled funding by a global coalition of governments, institutions, companies and NGOs, Jim O'Neill says in his review's final report on the topic, which outlines a menu of options for accomplishing that – including a levy on the pharma sector – and says a supra-national entity will also be needed to tackle AMR.